12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

BioDelivery sales and marketing update

BioDelivery said the U.S. relaunch of pain drug Onsolis fentanyl is being postponed so that two appearance issues raised by FDA can be addressed. The agency noted...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >